Clinical Trials
10 trialsNCT00352534 2026-06-03
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Children's Oncology Group
Phase 3 Completed
NCT00379340 2026-06-03
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Children's Oncology Group
Phase 3 Completed
NCT00667069 2025-06-05
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
UNICANCER
Phase 3 Completed
NCT00981656 2024-09-19
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00033631 2023-01-18
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00331773 2023-01-18
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00288080 2022-06-21
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00002602 2020-01-10
Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00528866 2019-04-24
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00551525 2017-07-25
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer
Radiation Therapy Oncology Group
Phase 2 Completed